ID   MDA-MB-435S
AC   CVCL_0622
SY   MDA-MB-435s; MDA-MB-435 S; MDA-MB-435-S; MDAMB435S; BrCL15
DR   BTO; BTO:0003941
DR   CLO; CLO_0007638
DR   CLDB; cl7142
DR   ArrayExpress; E-MTAB-2770
DR   ATCC; HTB-129
DR   BCRJ; 0165
DR   BioSample; SAMN10987989
DR   CCLE; MDAMB435S_SKIN
DR   CCRID; 3111C0001CCC000015
DR   CCRID; 3131C0001000700036
DR   CCRID; 3142C0001000000052
DR   CCTCC; GDC0053
DR   Cell_Model_Passport; SIDM01222
DR   CLS; 300277/NA
DR   Cosmic; 809237
DR   Cosmic; 871155
DR   Cosmic; 894089
DR   Cosmic; 904381
DR   Cosmic; 1044202
DR   Cosmic; 1046951
DR   Cosmic; 1287922
DR   Cosmic; 1289399
DR   Cosmic; 1523969
DR   Cosmic; 1609477
DR   Cosmic; 2301531
DR   DepMap; ACH-000884
DR   GEO; GSM149983
DR   GEO; GSM149991
DR   GEO; GSM149999
DR   GEO; GSM421877
DR   GEO; GSM887298
DR   GEO; GSM888373
DR   GEO; GSM1374657
DR   ICLC; HTL03006
DR   KCB; KCB 200773YJ
DR   LiGeA; CCLE_408
DR   LINCS_HMS; 50030
DR   LINCS_LDP; LCL-1307
DR   PRIDE; PXD016837
DR   Wikidata; Q54904637
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RX   PubMed=10700188;
RX   PubMed=12661003;
RX   PubMed=15677628;
RX   PubMed=16397213;
RX   PubMed=16541312;
RX   PubMed=19593635;
RX   PubMed=20070913;
RX   PubMed=22460905;
RX   PubMed=23601657;
RX   PubMed=28940260;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   https://www.atcc.org/support/faqs/91699/ATCC%20HTB-129%20Derivative-1051.aspx
WW   https://www.atcc.org/support/faqs/79d25/Morphology%20of%20ATCC%20HTB-129-495.aspx
WW   http://iclac.org/wp-content/uploads/Cross-Contaminations_v10_distribution.xlsx
WW   http://www.cellresource.cn/fdetail.aspx?id=15
WW   http://www.cellresource.cn/fdetail.aspx?id=606
WW   http://www.cellresource.cn/fdetail.aspx?id=820
CC   Problematic cell line: Contaminated. Parent cell line (MDA-MB-435) has been shown to be a M14 derivative.
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: KuDOS 95 cell line panel.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00565.
CC   Microsatellite instability: Stable (MSS) (PubMed=12661003).
CC   Sequence variation: Heterozygous for BRAF p.Val600Glu (c.1799T>A) (ClinVar=VCV000013961) (PubMed=19593635).
CC   Sequence variation: Heterozygous for CDKN2A c.150+2T>C (IVS1+2T>C); splice donor mutation and c.455insCdel26 (PubMed=19593635).
CC   Sequence variation: Hemizygous for EP300 p.Leu827Pro (c.3679T>C) and p.Glu1013Gly (4237A>G) (PubMed=10700188).
CC   Sequence variation: Heterozygous for TP53 p.Gly266Glu (c.797G>A) (ClinVar=VCV000161516) (PubMed=16541312).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.01%; Native American=0%; East Asian, North=2.13%; East Asian, South=0%; South Asian=0%; European, North=65.23%; European, South=32.63% (PubMed=30894373).
CC   Discontinued: CLS; 300277; true.
CC   Derived from metastatic site: Subcutaneous; right buttock.
ST   Source(s): ATCC; CCRID; CLS; PubMed=28940260
ST   Amelogenin: X
ST   CSF1PO: 11 (ATCC; CCRID; CLS)
ST   CSF1PO: 11,12 (PubMed=28940260)
ST   D12S391: 18,19
ST   D13S317: 12 (ATCC; CCRID; PubMed=28940260)
ST   D13S317: 12,13 (CLS)
ST   D16S539: 13
ST   D18S51: 13,17
ST   D19S433: 14 (CCRID)
ST   D19S433: 14,15 (CLS; PubMed=28940260)
ST   D1S1656: 12
ST   D21S11: 30
ST   D2S1338: 19,24
ST   D3S1358: 14 (CLS; PubMed=28940260)
ST   D3S1358: 14,20 (CCRID)
ST   D5S818: 11,12 (CCRID)
ST   D5S818: 12 (ATCC; CLS; PubMed=28940260)
ST   D6S1043: 11
ST   D7S820: 8 (PubMed=28940260)
ST   D7S820: 8,10 (ATCC; CCRID; CLS)
ST   D8S1179: 13 (CCRID; CLS)
ST   D8S1179: 13,14 (PubMed=28940260)
ST   FGA: 21
ST   Penta D: 9,11
ST   Penta E: 10,12
ST   TH01: 6,7
ST   TPOX: 8,11
ST   vWA: 16,18
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0417 ! MDA-MB-435
SX   Male
AG   33Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-07-20; Version: 29
//
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RA   Leibovitz A.;
RT   "Cell lines from human breast.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York (1994).
//
RX   PubMed=10700188; DOI=10.1038/73536;
RA   Gayther S.A., Batley S.J., Linger L., Bannister A., Thorpe K.,
RA   Chin S.-F., Daigo Y., Russell P., Wilson A., Sowter H.M.,
RA   Delhanty J.D.A., Ponder B.A.J., Kouzarides T., Caldas C.;
RT   "Mutations truncating the EP300 acetylase in human cancers.";
RL   Nat. Genet. 24:300-303(2000).
//
RX   PubMed=12661003; DOI=10.1002/gcc.10196;
RA   Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U.,
RA   Santibanez-Koref M.-F., Schlag P.M., Scherneck S.;
RT   "Identification of microsatellite instability and mismatch repair gene
RT   mutations in breast cancer cell lines.";
RL   Genes Chromosomes Cancer 37:29-35(2003).
//
RX   PubMed=15677628; DOI=10.1093/carcin/bgi032;
RA   Gorringe K.L., Chin S.-F., Pharoah P., Staines J.M., Oliveira C.,
RA   Edwards P.A.W., Caldas C.;
RT   "Evidence that both genetic instability and selection contribute to
RT   the accumulation of chromosome alterations in cancer.";
RL   Carcinogenesis 26:923-930(2005).
//
RX   PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853;
RA   Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M.,
RA   van den Ouweland A., Merajver S.D., Ethier S.P., Schutte M.;
RT   "BRCA1 mutation analysis of 41 human breast cancer cell lines reveals
RT   three new deleterious mutants.";
RL   Cancer Res. 66:41-45(2006).
//
RX   PubMed=16541312; DOI=10.1007/s10549-006-9186-z;
RA   Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.;
RT   "Thirteen new p53 gene mutants identified among 41 human breast cancer
RT   cell lines.";
RL   Breast Cancer Res. Treat. 99:97-101(2006).
//
RX   PubMed=19593635; DOI=10.1007/s10549-009-0460-8;
RA   Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F.,
RA   Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J.,
RA   Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M.,
RA   Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M.,
RA   Dinjens W.N.M., Ethier S.P., Clevers H., Jochemsen A.G., den Bakker M.A.,
RA   Foekens J.A., Martens J.W.M., Schutte M.;
RT   "Distinct gene mutation profiles among luminal-type and basal-type
RT   breast cancer cell lines.";
RL   Breast Cancer Res. Treat. 121:53-64(2010).
//
RX   PubMed=20070913; DOI=10.1186/1471-2407-10-15;
RA   Tsuji K., Kawauchi S., Saito S., Furuya T., Ikemoto K., Nakao M.,
RA   Yamamoto S., Oka M., Hirano T., Sasaki K.;
RT   "Breast cancer cell lines carry cell line-specific genomic alterations
RT   that are distinct from aberrations in breast cancer tissues:
RT   comparison of the CGH profiles between cancer cell lines and primary
RT   cancer tissues.";
RL   BMC Cancer 10:15-15(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23601657; DOI=10.1186/bcr3415;
RA   Riaz M., van Jaarsveld M.T.M., Hollestelle A.,
RA   Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.,
RA   Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A.,
RA   Martens J.W.M.;
RT   "miRNA expression profiling of 51 human breast cancer cell lines
RT   reveals subtype and driver mutation-specific miRNAs.";
RL   Breast Cancer Res. 15:R33-R33(2013).
//
RX   PubMed=28940260; DOI=10.1002/ijc.31067;
RA   Korch C., Hall E.M., Dirks W.G., Ewing M., Faries M., Varella-Garcia M.,
RA   Robinson S., Storts D.R., Turner J.A., Wang Y., Burnett E.C., Healy L.,
RA   Kniss D., Neve R.M., Nims R.W., Reid Y.A., Robinson W.A.,
RA   Capes-Davis A.;
RT   "Authentication of M14 melanoma cell line proves misidentification of
RT   MDA-MB-435 breast cancer cell line.";
RL   Int. J. Cancer 142:561-572(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//